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Abstract
At the end of 2019, coronavirus disease-2019 (COVID-19) started to spread worldwide and caused a pandemic 
in March 2020. Epidemiologic data of COVID-19 in the pediatric population are not certain. The pandemic also 
decreases routine immunization coverage in children which lead to increased risk of vaccine-preventable disease 
outbreak. Routine immunization practice should be continued with due regard to health protocol. Children in contact 
with COVID-19 patients or children who previously have COVID-19 may be immunized after 14 days of symptom-
free or confirmed negative by two polymerase chain reaction tests at a minimum interval of 24 h. Bacillus Calmette–
Guerin, influenza, and pneumococcal immunization give a positive effect on COVID-19. Until present, there is no 
available vaccine for COVID-19.
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Introduction
In December 2019, a cluster of patients in 
contact with a market in Wuhan, Hubei Province, China, 
was hospitalized due to pneumonia with unknown 
etiology [1], [2]. Further, investigations confirmed that 
the disease was caused by a virus named severe acute 
respiratory syndrome-coronavirus-2 (SARS-CoV-2), and 
the disease was named as CoV disease-2019 (COVID-
19) [3]. In March 2020, the disease had spread to Europe, 
and on March 11, 2020, the World Health Organization 
(WHO) declared COVID-19 as a pandemic [1], [2]. 
Children, health-care staffs, and elderly population are at 
a higher risk for SARS-CoV-2 infection [1]. Unfortunately, 
screening for COVID-19 is less frequently done in the 
pediatric population due to asymptomatic disease course 
in this population, giving uncertain epidemiological data 
regarding the disease [2], [3]. Children are less affected 
by COVID-19 compared to adults, with only about 2% 
of total cases in China and 1.2% in Italy [3], [4]. There 
was no evidence regarding vertical transmission from 
mother to child [1], [2], [3]. However, antibody toward 
SARS-CoV-2 was detected in newborns from mothers 
with COVID-19 [3].
The most common clinical manifestations of 
COVID-19 in children are fever (51.6%), cough (47.3%), 
and sore throat (17.9%) [2], [3]. Extra-respiratory 
symptoms commonly found are diarrhea (9.7%), 
vomiting (7.2%), and fatigue (10.6%) [3], [4]. The real-
time polymerase chain reaction from the nasopharyngeal 
swab is considered as the gold standard for diagnosing 
COVID-19. At present, there is no specific treatment for 
COVID-19. Broad-spectrum antiviral and antibiotics are 
utilized. Corticosteroid and intravenous immunoglobulin 
(Ig) are given for children with severe cases [1], [3]. The 
estimated mortality for children with COVID-19 from a 
systematic review was 0.08% [3].
A vaccine against COVID-19 is considered as 
the most important and powerful weapon to fight the 
disease. Unfortunately, until the present, there is no 
effective vaccine which has been discovered [2]. During 
this pandemic, many countries urge shelter-in-place or 
stay-at-home policy. This policy, in addition to parental 
anxiety regarding COVID-19 transmission to their 
children, extremely decreased routine immunization 
coverage. This condition increases the risk of vaccine-
preventable disease outbreak during or after COVID-19 
pandemic [5]. Data from the Ministry of Health Republic 
of Indonesia showed that 84% of primary health facilities 
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stopped or postponed immunization practice. National 
immunization coverage was also decreased during 
COVID-19 pandemic, with a range between 0.5% and 
87% [6]. We aimed to describe pediatric immunization 
during COVID-19 pandemic and to discuss about the 
effects of routine immunization both in reducing vaccine-
preventable diseases and modulate COVID-19.
Pediatric Immunization During COVID-19 
Pandemic
Immunization is one of the most important 
inventions in the medical world. It greatly reduces morbidity 
and mortality from several diseases, such as smallpox, 
tuberculosis, and polio [7], [8]. Routine immunization must 
be conducted to prevent vaccine-preventable diseases 
outbreak even in COVID-19 pandemic [7], [9], [10]. 
Prevention of vaccine-preventable diseases outbreak 
gives huge advantages during this pandemic, such as 
saving lives and saving resources [7], [10]. Immunization 
practice may also be used to spread messages regarding 
COVID-19 prevention and to identify early signs and 
symptoms of COVID-19 [10]. Parents or proxy should be 
informed about the importance of completion of routine 
immunization because if an outbreak occurred, we will 
face a double burden: COVID-19 pandemic and vaccine-
preventable disease outbreak [6].
Immunization practice in children should follow 
health protocol for decreasing the risk of exposure to 
subjects with COVID-19 [9], [10]. Before bringing children 
for immunization, parent and proxy are suggested to make 
an appointment. This is important to avoid overcrowded 
rooms [7]. The crowded situation should be minimized 
by limiting the number of adult who accompanies the 
child [10]. Children’s companions should be screened 
for fever and other COVID-19 symptoms [7]. The area 
for immunization practice should be well ventilated 
and frequently disinfected [7], [10]. The area should be 
spacious enough with airflow from health personnel to 
children. Entrance and exit doors should be separated [7]. 
The separation between well and sick visits, by modifying 
clinic structure, rescheduling visits, and physical spacing, 
is important. Younger infants are prioritized to receive 
immunizations [5], [7], [9], [10]. All health-care personnel 
should use complete personal protective equipments and 
practice hand hygiene as often as possible [7], [10]. In 
a situation of personal protective equipment shortage, 
health-care personnel should minimally wear the medical 
mask and fresh gloves for each child. Children should 
wait for 30 min after immunization in a separated place to 
monitor vaccine-associated adverse reaction [7].
Children in contact with COVID-19 patients 
or suspected for COVID-19 may still receive routine 
immunization since there is no evidence of contraindications 
reported. However, they should be free from symptoms 
for 14 days or preferably tested negative for COVID-19 
in two consecutive samplings within 24 h interval before 
immunization [7], [10]. Catch-up immunization should 
also be continued during this pandemic with similar 
health protocol with routine immunization [5], [7], [10]. 
Mobile immunization facility may be optimized to deliver 
the vaccine to children in remote areas or children who 
missed their vaccination schedule [7]. School-based 
immunization is still applicable if conducted with proper 
health protocol [5], [10].
At present, there is no specific vaccine 
against COVID-19 [10]. Influenza immunization is 
suggested during COVID-19 pandemic. The reason 
is to lower the probability of having influenza which 
has similar symptoms with COVID-19. By receiving 
influenza immunization, health-care personnel may at 
least exclude influenza as the etiology of respiratory 
symptoms [9]. Passive immunization, using polyclonal 
and monoclonal antibodies, is being investigated 
for COVID-19 while waiting for the vaccine. Passive 
immunization is a process of administering mature 
antibodies to treat infectious diseases. It can occur 
naturally or artificially. The antibody may be obtained 
from the serum of immunized animals or convalescent 
humans. However, harvesting antibodies require a 
very high cost. IgY is one of the several candidates for 
COVID-19 passive immunization. IgY is produced by 
birds, reptiles, and amphibians, but its function is similar 
to IgG in mammals. IgY has been used in immunization 
against several microorganisms such as Salmonella 
sp. and rotavirus. Continuous investigations are being 
held to obtain SARS-CoV-2 specific IgY [11].
The Role of Immunization in COVID-19
Bacillus Calmette–Guerin (BCG) vaccination 
is reported to be correlated with the incidence and 
outcome of COVID-19. BCG vaccination decreases 
the incidence and alleviates the outcome of COVID-19 
in countries which adopt mandatory BCG vaccination 
program [4], [8], [12], [13]. A study reported that 
countries which apply universal BCG immunization 
had a significantly lower incidence and mortality rates 
compared to those who do not apply universal BCG 
vaccination program [13]. Furthermore, BCG strain also 
affects its protective effect against COVID-19. Countries 
with early strains BCG (Japan and Russia) show a lower 
incidence of COVID-19 compared to countries with late 
strains (Denmark). On the other hand, the protective 
effect of BCG vaccination is affected by other factors, 
as reported by data from Finland and Australia. Both 
countries reported low mortality rates from COVID-19 
even they had stopped BCG vaccination in their 
regions [12]. Some factors which affect this result are 
national disease burden, the difference in testing rate, 
isolation policy, and demographic parameter [8].
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The protective effect of BCG is possible because 
BCG vaccination is reported to be able to elicit protection 
against other pathogens through sustained changes in 
the innate and adaptive immune systems. BCG induces 
histone modifications and epigenetic reprogramming of 
interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF). 
This results in known as “trained immunity” [4], [8], [12], [13]. 
The concept of trained immunity was introduced in 2011. 
According to the concept, bacterial infection induces cross-
protection against other pathogens. Unfortunately, this 
cross-protection is temporary and quickly disappeared. 
However, memory lymphocytes triggered by the infection 
may also provide longer-term cross-protection [4]. In vivo 
studies have confirmed this effect against avian influenza 
A and yellow fever viruses [8].
Vaccines may also contain immune adjuvant 
which promotes innate immune function. Influenza 
vaccination is hypothesized to have a protective effect 
against SARS-CoV-2 since the S-glycoprotein of 
SARS-CoV-2 has similarities with the hemagglutinin 
antigen glycoprotein in the influenza virus. Pneumococcal 
conjugate and polysaccharide vaccines are also 
suspected to have an advantage in preventing bacterial 
coinfection in COVID-19 children. Investigations 
regarding the effect of available immunization on 
COVID-19 are being conducted [4]. The WHO has not 
approved the utilization of any vaccine for COVID-19 
management until valid evidence becomes available [8]. 
The authors did not find any study or report regarding 
the contribution of other vaccines in the incidence and 
outcome of patients with COVID-19.
Conclusion
Routine pediatric immunization practice during 
COVID-19 pandemic must be carried out while still 
applying standard health protocol. Children in contact with 
COVID-19 patients or previously have that COVID-19 
should be immunized 14 days after the symptom 
diminished or after COVID-19 showed a negative result. 
BCG, influenza, and pneumococcal immunization give 
particular positive effects on COVID-19. Until present, 
there is no specific vaccine for COVID-19.
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